Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934231 | 0.91 | KMT2A (0.55) | KMT2AALDH1A1KDM4ELMNANPSR1 | |
| SCHEMBL9935464 | 0.89 | MAPT (0.51) | KMT2AALDH1A1DGAT2TP53TSHR | |
| SCHEMBL9934664 | 0.89 | MAPT (0.51) | KMT2AALDH1A1DGAT2TP53TSHR | |
| SCHEMBL9933790 | 0.89 | MAPT (0.51) | KMT2AALDH1A1DGAT2TP53TSHR | |
| SCHEMBL9934138 | 0.89 | LMNA (0.44) | KMT2AALDH1A1DGAT2KDM4ELMNA | |
| SCHEMBL9934450 | 0.89 | MAPT (0.44) | KMT2AALDH1A1DGAT2KDM4ELMNA | |
| SCHEMBL9933466 | 0.88 | TSHR (0.54) | KMT2AALDH1A1DGAT2KDM4ELMNA | |
| SCHEMBL9932874 | 0.87 | EPHX2 (0.48) | KMT2AALDH1A1DGAT2KDM4ETSHR | |
| SCHEMBL9933957 | 0.86 | ALDH1A1 (0.52) | KMT2AALDH1A1DGAT2NPSR1TP53 | |
| SCHEMBL9973897 | 0.86 | TSHR (0.59) | KMT2AALDH1A1KDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | HARRIS III RALPH NEW (US) | 2012-06-21 | — | — | US | claimed |
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | HARRIS III RALPH NEW (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | HARRIS III RALPH NEW (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | HARRIS III RALPH NEW (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | P2RX7, P2RX3, P2RX1 | KMT2A 4820/4885ALDH1A1 820/4885DGAT2 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.